RESUMO
BACKGROUND: Persisting cancer-related fatigue impairs health-related quality of life (HRQoL) and social reintegration in patients with Hodgkin's lymphoma (HL). The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided by positron emission tomography after two cycles (PET-2) as new standard. Here, we investigate the impact of treatment de-escalation on long-term HRQoL, time to recovery from fatigue (TTR-F), and time to return to work (TTR-W). PATIENTS AND METHODS: Patients received European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and life situation questionnaires at baseline, interim, end of treatment, and yearly follow-up. TTR-F was defined as time from the end of chemotherapy until the first fatigue score <30. TTR-W was analyzed in previously working or studying patients and measured from the end of treatment until the first documented work or education. We compared duration of treatment on TTR-F and TTR-W using Cox proportional hazards regression adjusted for confounding variables. RESULTS: HRQoL questionnaires at baseline were available in 1632 (83.9%) of all randomized patients. Overall, higher baseline fatigue and age were significantly associated with longer TTR-F and TTR-W and male sex with shorter TTR-W. Treatment reduction from eight to four chemotherapy cycles led to a significantly shorter TTR-F [hazard ratio (HR) 1.41, P = 0.008] and descriptively shorter TTR-W (HR 1.24, P = 0.084) in PET-2-negative patients. Reduction from six to four cycles led to non-significant but plausible intermediate accelerations. The addition of rituximab caused significantly slower TTR-F (HR 0.70, P = 0.0163) and TTR-W (HR 0.64, P = 0.0017) in PET-2-positive patients. HRQoL at baseline and age were the main determinants of 2-year HRQoL. CONCLUSIONS: Individualized first-line treatment in patients with advanced-stage HL considerably shortens TTR-F and TTR-W in PET-2-negative patients. Our results support the use of response-adapted shortened treatment duration for patients with HL.
Assuntos
Doença de Hodgkin , Humanos , Masculino , Doença de Hodgkin/patologia , Qualidade de Vida , Retorno ao Trabalho , Fadiga/etiologia , Sobreviventes , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêuticoRESUMO
The G protein-coupled receptor 56 (GPR56) was identified as part of the molecular signature of functionally validated leukemic stem cells isolated from patients with acute myeloid leukemia (AML). This report now demonstrates particularly high expression of GPR56 in patients with mutant NPM1 and FLT3-length mutation and association of high GPR56 expression with inferior prognosis in a large patient cohort treated in two independent multicenter phase III trials. Functional relevance of GPR56 expression was validated in mice, in which co-expression of Gpr56 significantly accelerated HOXA9-induced leukemogenesis and vice versa knockdown of Gpr56 delayed onset of HOXA9/MEIS1-induced AML. Overexpression of Gpr56 grossly changed the molecular phenotype of Hoxa9-transduced cells affecting pathways involved in G protein-coupled receptors (GPRCs) and associated intracellular signaling. Blockage of surface GPR56 by an anti-GPR56 antibody successfully impaired engraftment of primary human AML cells. In summary, these data demonstrate that high expression of GPR56 is able to contribute to AML development and characterize the GPR56 as a potential novel target for antibody-mediated antileukemic strategies.
Assuntos
Leucemia Mieloide Aguda/etiologia , Receptores Acoplados a Proteínas G/fisiologia , Animais , Carcinogênese , Feminino , Xenoenxertos , Proteínas de Homeodomínio/fisiologia , Humanos , Masculino , Camundongos , Proteína Meis1 , Proteínas de Neoplasias/fisiologia , Nucleofosmina , Receptores Acoplados a Proteínas G/deficiência , Receptores Acoplados a Proteínas G/genéticaRESUMO
Although the transforming potential of Hox genes is known for a long time, it is not precisely understood to which extent splicing is important for the leukemogenicity of this gene family. To test this for Hoxa9, we compared the leukemogenic potential of the wild-type Hoxa9, which undergoes natural splicing, with a full-length Hoxa9 construct, which was engineered to prevent natural splicing (Hoxa9FLim). Inability to undergo splicing significantly reduced in vivo leukemogenicity compared to Hoxa9-wild-typed. Importantly, Hoxa9FLim could compensate for the reduced oncogenicity by collaborating with the natural splice variant Hoxa9T, as co-expression of Hoxa9T and Hoxa9FLim induced acute myeloid leukemia (AML) after a comparable latency time as wild-type Hoxa9. Hoxa9T on its own induced AML after a similar latency as Hoxa9FLim, despite its inability to bind DNA. These data assign splicing a central task in Hox gene mediated leukemogenesis and suggest an important role of homeodomain-less splice variants in hematological neoplasms.
Assuntos
Processamento Alternativo , Proteínas de Homeodomínio/genética , Leucemia Mieloide Aguda/etiologia , Adulto , Animais , Proteínas de Homeodomínio/fisiologia , Humanos , Leucemia Mieloide Aguda/genética , Camundongos , Camundongos Endogâmicos C3H , Camundongos Endogâmicos C57BLAssuntos
Perfilação da Expressão Gênica , Leucemia Linfocítica Crônica de Células B , Análise de Sobrevida , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Leucemia Linfocítica Crônica de Células B/genética , Leucemia Linfocítica Crônica de Células B/mortalidade , Leucemia Linfocítica Crônica de Células B/terapia , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase em Tempo RealRESUMO
Identification of numerous criteria important in the pathogenesis, biology, prognosis and treatment of the different types of leukemia necessitates a broad spectrum of diagnostic methods for the initial diagnosis and in the further course of the disease. In addition to cytomorphology with cytochemistry, which is been path-breaking for the application of further diagnostic methods, cytogenetics has become an obligatory diagnostic tool. Immunophenotyping and, even more relevant, molecular genetics plays an important role. Other diagnostic techniques are widely developed. The diagnostic procedures are described, with a focus on their mode of operation as well as their clinical significance. Because of their high clinical relevance and growing complexity, the diagnosis of leukemias should be performed in specialized laboratories.
Assuntos
Leucemia/diagnóstico , Adulto , Análise Citogenética , Técnicas Citológicas , Histocitoquímica , Humanos , Imunofenotipagem , Hibridização in Situ Fluorescente/métodos , Neoplasia Residual/diagnóstico , Análise de Sequência com Séries de Oligonucleotídeos , Reação em Cadeia da Polimerase , PrognósticoRESUMO
Molecular characterization of acute lymphoblastic leukemia (ALL) has greatly improved the ability to categorize and prognostify patients with this disease. In this study, we show that the proto-oncogene CDX2 is aberrantly expressed in the majority of cases with B-lineage ALL and T-ALL. High expression of CDX2 correlated significantly with the ALL subtype pro-B ALL, cALL, Ph(+) ALL and early T-ALL. Furthermore, high expression of CDX2 was associated with inferior overall survival and showed up as a novel and strong risk factor for ALL in bivariate analysis. Functional analyses showed that overexpression of Cdx2 in murine bone marrow progenitors perturbed genes involved in lymphoid development and that depletion of CDX2 in the human ALL cell line Nalm6 inhibited colony formation. These data indicate that aberrant CDX2 expression occurs frequently and has prognostic impact in adult patients with ALL.
Assuntos
Regulação Neoplásica da Expressão Gênica , Genes Homeobox , Proteínas de Homeodomínio/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Leucemia-Linfoma Linfoblástico de Células Precursoras/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Células da Medula Óssea/patologia , Fator de Transcrição CDX2 , Linhagem Celular Tumoral , Feminino , Proteínas de Homeodomínio/análise , Humanos , Masculino , Pessoa de Meia-Idade , Proteínas de Neoplasias/análise , Proteínas de Neoplasias/genética , Leucemia-Linfoma Linfoblástico de Células Precursoras/classificação , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Prognóstico , Proto-Oncogene Mas , Proto-Oncogenes , Taxa de Sobrevida , Adulto JovemRESUMO
Leukocytosis is a condition often met with in the clinical and ambulatory setting. Although it is usually caused by an increase in the numbers of neutrophilic granulocytes, an increase in other leukocytes populations may also account for leukocytosis. Etiologically, both primary pathological conditions affecting the white blood cells, such as various forms of leukemia and lymphomas, and also rare genetic disorders must be considered. Decidedly more common, however, are reactive changes caused by infections, cigarette smoking, chronic inflammation, necrotic tissue or certain drugs. Although moderate leukocytosis in the absence of a clinical correlate and/or an apparent trigger, requires no diagnostic clarification, it should be kept under observation. If the etiology is uncertain, or a treatment-requiring disorder is suspected, the differential blood count is at the focus of the further diagnostic work-up. Depending upon the findings, this is supplemented by additional laboratory parameters, bone marrow examination, microbiological investigations and imaging procedures. Leukostasis resulting from vasoocclusion in the presence of very high numbers of leukocytes represents an emergency situation, and is an indication for leukapheresis.
Assuntos
Infecções/diagnóstico , Inflamação/diagnóstico , Contagem de Leucócitos , Leucocitose/etiologia , Diagnóstico Diferencial , Medicina de Família e Comunidade , Humanos , Infecções/imunologia , Inflamação/imunologia , Leucocitose/imunologiaRESUMO
Thrombocytopenia is present when the number of platelets drops to below 150 G/l. Leaving aside pseudothrombocytopenia, such a situation may be triggered by pregnancy or a range of different drugs, or may signify the presence of idiopathic thrombocytopenic purpura (ITP). Thrombocytosis is present when the platelet count exceeds 500 G/l. This condition includes a large variety of forms of reactive thrombocytosis, a clonal increase in thrombocytes in hematological diseases, and the rare condition of familial thrombocytosis.
Assuntos
Achados Incidentais , Trombocitopenia/etiologia , Trombocitose/etiologia , Anemia Ferropriva/sangue , Anemia Ferropriva/diagnóstico , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Feminino , Neoplasias Hematológicas/sangue , Neoplasias Hematológicas/diagnóstico , Humanos , Infecções/sangue , Infecções/diagnóstico , Inflamação/sangue , Inflamação/diagnóstico , Síndromes Mielodisplásicas/sangue , Síndromes Mielodisplásicas/diagnóstico , Neoplasias/sangue , Neoplasias/diagnóstico , Contagem de Plaquetas , Gravidez , Complicações Hematológicas na Gravidez/sangue , Complicações Hematológicas na Gravidez/diagnóstico , Púrpura Trombocitopênica Idiopática/sangue , Púrpura Trombocitopênica Idiopática/diagnóstico , Trombocitose/sangue , Trombocitose/diagnósticoRESUMO
An increase in Hb levels, haematocrit or the absolute number of red blood cells may be evidence of polycythemia rubra vera. Much more commonly, however, erythrocytosis is due to an underlying non-hematological disease. To establish the diagnosis of polycythemia, a secondary polyglobulia must first be excluded. If no evidence of polyglobulia is found, or if EPO levels are decreased, or splenomegaly not accountable for by portal hypertension is present, a specific diagnostic work-up must be performed by a hematologist/oncologist. This includes a bone marrow aspiration, cytological examination and molecular genetic testing.
Assuntos
Contagem de Eritrócitos , Hematócrito , Hemoglobinometria , Policitemia/etiologia , Adulto , Algoritmos , Diagnóstico Diferencial , Medicina de Família e Comunidade , Feminino , Humanos , Masculino , Policitemia/diagnóstico , Policitemia Vera/diagnóstico , Policitemia Vera/etiologia , Valores de ReferênciaAssuntos
Subunidade alfa 2 de Fator de Ligação ao Core/fisiologia , Proteínas de Ligação a DNA/fisiologia , Regulação Leucêmica da Expressão Gênica , Janus Quinase 2/fisiologia , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/patologia , Transtornos Mieloproliferativos/patologia , Proteínas Proto-Oncogênicas/fisiologia , Fatores de Transcrição/fisiologia , Citoplasma/metabolismo , Progressão da Doença , Feminino , Humanos , Hibridização in Situ Fluorescente , Leucemia Mieloide Aguda/metabolismo , Pessoa de Meia-Idade , Modelos Genéticos , Mutação , Transtornos Mieloproliferativos/metabolismo , Proteína 1 Parceira de Translocação de RUNX1 , Fatores de Transcrição/metabolismoRESUMO
Genetic and molecular techniques have provided increasing insights into the biology of acute myeloid leukemia (AML). These investigations showed that AML is not a homogeneous disease but a heterogeneous group of biologically different subentities. These subentities are currently primarily defined by cytogenetics and molecular markers. They differ substantially in response to therapy and long-term outcome and hence allow different risk groups of patients to be defined. These will guide therapeutic decisions in future therapeutic strategies and may ultimately lead to an individualized treatment concept.
Assuntos
Antineoplásicos/administração & dosagem , Antineoplásicos/classificação , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/tratamento farmacológico , Medição de Risco/métodos , Humanos , Leucemia Mieloide Aguda/classificação , Guias de Prática Clínica como Assunto , Padrões de Prática Médica , Fatores de RiscoRESUMO
In recent years much progress has been made in the understanding of the biology of hematopoietic stem cells (HSC) and their involvement in normal blood cell development. Using immunophenotyping it is possible, to enrich HSC, however, so far we are not able to positively select HSC. For the identification, characterization and quantification of HSC it is necessary to use functional assay systems, such as xenotransplantation models. HSC from bone marrow, peripheral blood and in some cases also cord blood have been used for years in transplantation settings especially in patients with leukemia. A better understanding of the mechanisms underlying stem cell regulation as well as stem cell self renewal would have clinical implications e. g. for clinical transplantation strategies. A number of hematological diseases such as chronic myeloid leukemia originates from a malignant transformed HSC. A better understanding of the biology of normal as well as malignant HSC is therefore crucial not only for a better understanding of the disease, but also for the development of strategies aiming at the discrimination of normal and malignant stem cell candidates and the development of therapies targeting the leukemic stem cell.
Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Células-Tronco Hematopoéticas/fisiologia , Transformação Celular Neoplásica/patologia , Ensaio de Unidades Formadoras de Colônias , Doenças Hematológicas/sangue , Doenças Hematológicas/terapia , Humanos , Imunofenotipagem , Leucemia/sangue , Leucemia/terapiaRESUMO
In hematological malignancies, gene expression profiling using DNA-microarrays led to the discovery of novel lymphoma and leukemia subgroups. The heterogeneous entity of diffuse large B-cell lymphoma could be subdivided into the germinal center B-cell-like and the activated B-cell-like subtype which differ in pathogenesis and clinical behavior. In leukemia, existing entities defined by morphological, cytogenetic, molecular and immunophenotypic criteria were confirmed on the global gene expression level; in addition, new important molecular subgroups could be identified. In retrospective clinical lymphoma and leukemia studies, robust gene expression signatures were discovered that predict the clinical course at the time of diagnosis. Given the huge potential of the DNA-microarray technology, application in the routine diagnostic setting appears possible.
Assuntos
Biomarcadores Tumorais/análise , Leucemia/diagnóstico , Leucemia/metabolismo , Linfoma/diagnóstico , Linfoma/metabolismo , Proteínas de Neoplasias/análise , Análise de Sequência com Séries de Oligonucleotídeos/métodos , Perfilação da Expressão Gênica/métodos , Humanos , Análise de Sequência com Séries de Oligonucleotídeos/instrumentação , Análise de Sequência com Séries de Oligonucleotídeos/tendênciasRESUMO
The detailed characterization of genetic and molecular aberrations in acute myeloid leukemia (AML) has substantially improved our understanding of the pathogenesis of this disease. With an incidence of up to 12% in all AML cases, the translocation t(8;21), forming the AML1-ETO fusion gene, is one of the most common genetic aberrations in AML. Experimental data have shown that AML1-ETO is not sufficient to induce leukemia by itself, but has to collaborate with other genetic alterations for leukemic transformation. These data are supported by observations in AML patients, who recurrently show activating mutations of the receptor tyrosine kinase FLT3 or c-KIT together with the AML1-ETO fusion gene. These findings might have clinical implications and provide a rationale to test RTK inhibitors in the treatment of patients with core binding factor AML and concurrent activating RTK mutations.
Assuntos
Cromossomos Humanos Par 21/genética , Cromossomos Humanos Par 8/genética , Subunidade alfa 2 de Fator de Ligação ao Core/genética , Leucemia/genética , Leucemia/patologia , Proteínas de Fusão Oncogênica/genética , Translocação Genética/genética , Subunidade alfa 2 de Fator de Ligação ao Core/metabolismo , Humanos , Modelos Genéticos , Proteínas de Fusão Oncogênica/metabolismo , Proteína 1 Parceira de Translocação de RUNX1RESUMO
Genetic and molecular techniques have provided increasing insights into the biology of acute myeloid leukemia (AML). These investigations showed that AML is not a homogeneous disease but a heterogeneous group of biologically different subentities. These subentities are currently primarily defined by cytogenetics by which three main subgroups can be discriminated: AML with balanced translocations, AML with unbalanced aberrations and AML without cytogenetically detectable aberrations. Within the latter group molecular alterations are identified in more than half of cases such as NPM mutations, FLT3 mutations, MLL duplications and mutations of CEBP-alpha. The clinical meaning of these findings is illustrated by substantial differences in response to therapy and long-term outcome. As demonstrated by the recent multicenter trial of the German AML Cooperative Group (AMLCG) and other studies intensification of induction therapy may improve the results in distinct subtypes but fails to do so in others. Therefore, new strategies need to be explored which incorporate the knowledge about the biology of AML to develop biology adapted treatment strategies. This process has just begun and is predominantly determined by the availability of new agents and their evaluation in clinical phase I and II studies. A variety of targets are currently explored and some trials have yielded promising results already. The step towards a biology adapted treatment of AML is long and requires the combined efforts of researchers, clinicians and the pharmaceutical industry. The first steps towards this goal have been taken and give rise to the hope for more effective and more specific therapies of AML.
Assuntos
Leucemia Mieloide Aguda/terapia , Terapia Combinada/métodos , Humanos , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/patologia , Proteínas de Neoplasias/genética , Translocação Genética/genéticaRESUMO
Primitive malignant progenitors defined as nonobese diabetic/severe combined immunodeficient (NOD/SCID) leukemia-initiating cells or NOD/SL-IC from patients with acute myeloid leukemia (AML) can be detected and quantitated in sublethally irradiated NOD/SCID mice. However, there is variability in the levels of bone marrow (BM) engraftment obtained after intravenous injection of cells from different AML samples. In the current study, AML cell engraftment in standard NOD/SCID mice was compared to that obtained with NOD/SCID mice transgenic for the human growth factor genes Steel factor (SF), interleukin-3 (IL-3) and granulocyte macrophage-colony-stimulating factor (GM-CSF) (N/S-S/GM/3) as well as beta 2 microglobulin-null NOD/SCID (N/S-beta 2m(-/-)) mice. Three of the eight AML samples that failed to engraft in standard NOD/SCID animals showed easily detectable and up to 70-fold increased in the number of leukemic cells in BM 8-12 weeks post-transplantation in each of the N/S-beta 2m(-/-) and N/S-S/GM/3 mouse strains. In two of the four AML samples studied at limiting dilution, the frequency of NOD/SL-IC detected was increased six- and seven-fold. Thus, in these novel mouse strains a broader spectrum of AML patient samples can be evaluated for their progenitor content and potentially studied for their response to innovative therapeutics in vivo.
Assuntos
Fator Estimulador de Colônias de Granulócitos e Macrófagos/fisiologia , Interleucina-3/fisiologia , Leucemia Mieloide/patologia , Transplante de Neoplasias , Fator de Células-Tronco/fisiologia , Transplante Heterólogo , Microglobulina beta-2/deficiência , Doença Aguda , Animais , Medula Óssea/patologia , Citometria de Fluxo , Sobrevivência de Enxerto , Fator Estimulador de Colônias de Granulócitos e Macrófagos/genética , Humanos , Hibridização in Situ Fluorescente , Interleucina-3/genética , Camundongos , Camundongos Endogâmicos NOD , Camundongos Knockout , Camundongos SCID , Camundongos Transgênicos , Quimera por Radiação , Proteínas Recombinantes de Fusão/fisiologia , Fator de Células-Tronco/genética , Microglobulina beta-2/genéticaRESUMO
Acute myeloid leukemia (AML) is a heterogeneous group of disorders that can be discriminated by morphology, immunophenotyping or more recently by cytogenetic and molecular techniques. By cytogenetics two major groups of AML can be discriminated: One group with detectable chromosomal aberrations accounting for approximately 52 % of all de novo AML and the second group without cytogenetically detectable karyotype abnormalities. In the first group two major subtypes can be further distinguished. The first group comprises AML with balanced aberrations mainly consisting in t(8;21), t(15;17) and inv(16). The second group comprizes cases with unbalanced aberrations including particularly 5q-, 17q- -5 and AML with complex karyotypes. AMLs with balanced aberrations have a good prognosis with long term survival being achieved in approximately 60 %-80 % of cases. AMLs with non-balanced aberrations on the other hand have a poor prognosis with only 10 %-15 % long-term survivors. AMLs with no detectable abnormalities or other cytogenetic aberrations comprise a group with an intermediate prognosis in which long term survival is achieved in approximately 25 %-30 % of cases. Biologically, AMLs with balanced aberrations regularly involve the deregulation of transcription factors resulting in an impairment of cell differentiation and proliferation. AMLs with unbalanced aberrations are mostly characterized by a loss of genetic material resulting in an alteration of cell cycle control and DNA repair. A new view on the biology of AML has recently been made possible through the analysis of gene expression profiles. This technique is still under investigation. First results, however, already show that gene expression patterns have a high diagnostic potential and allow to detect biology subgroups with a high accuracy. Furthermore, by this technique pathways can be identified that are altered in the leukemic process. Gene expression profiling therefore opens a new and exciting perspective in leukemia biology and therapy that may have substantial impact on the improvement of diagnosis and more importantly may guide therapeutic strategies.
Assuntos
Aberrações Cromossômicas , Leucemia Mieloide/patologia , Doença Aguda , Idade de Início , Perfilação da Expressão Gênica , Humanos , Incidência , Cariotipagem , Leucemia Mieloide/epidemiologia , Leucemia Mieloide/genética , Leucemia Mieloide/terapiaRESUMO
The transcription factor AML1 (CBFA2) is indispensable for early fetal hematopoiesis, but also transactivates target genes which are important for further downstream hematopoiesis. However, little is known about the impact of AML1 on lineage-committed stages. We investigated the transcription of AML1 in subfractions of four normal adult bone marrow aspirates isolated by fluorescence-activated cell sorting. AML1 is transcribed in early (CD34+/CD38-) and late (CD34+/CD38+) hematopoietic progenitors, B-cell precursors (CD10+/CD19+) as well as in immature monocytes (CD14-/CD11c+), myeloid (CD15+/CD33+ and CD15+/CD33-) and erythroid (GPA+/CD3-/CD45-) cells, but not in T lymphocytes (GPA-/CD3+/CD45+). These data suggest that in adult hematopoiesis AML1 may be critically involved in differentiation of early hematopoietic progenitors, erythroid cells, and lymphoid precursors. These subfractions are interesting targets to study the importance of AML1 in definitive hematopoiesis.